Risk Assessment and Risk Minimization in Nanomedicine: A Need for Predictive, Alternative, and 3Rs Strategies.
Risk Assessment and Risk Minimization in Nanomedicine: A Need for Predictive, Alternative, and 3Rs Strategies.
复制标题
DOI：
10.3389/fphar.2018.00228
复制
发表时间：
2018
影响因子：
5.6
通讯作者：
Giachino C
中科院分区：
文献类型：
--
作者：
Accomasso L;Cristallini C;Giachino C
纳米材料在医学上的使用增长非常迅速，这引发了人们对可能的健康风险的担忧。当然，纳米技术在医学上的应用具有许多重大潜力，因为它至少可以通过三种不同的方式改善人类健康：有助于疾病的早期诊断、改善治疗结果和控制医疗成本。然而，毒理学或安全评估是任何新的医疗技术不可或缺的一部分，纳米技术也不例外。在这个框架中，纳米安全研究的主要目的是使纳米药物的设计更加安全。最迫切的需要是寻找和验证能够推断急性体外结果的新方法，以预测慢性体内效应，为此已经发起了几项欧洲倡议。虽然“设计安全”的过程可能被认为是理所当然的，但在纳米医学领域，“设计更安全”可能是一个可以达到的目标。
The use of nanomaterials in medicine has grown very rapidly, leading to a concern about possible health risks. Surely, the application of nanotechnology in medicine has many significant potentialities as it can improve human health in at least three different ways: by contributing to early disease diagnosis, improved treatment outcomes and containment of health care costs. However, toxicology or safety assessment is an integral part of any new medical technology and the nanotechnologies are no exception. The principle aim of nanosafety studies in this frame is to enable safer design of nanomedicines. The most urgent need is finding and validating novel approaches able to extrapolate acute in vitro results for the prediction of chronic in vivo effects and to this purpose a few European initiatives have been launched. While a “safe-by-design” process may be considered as utopic, “safer-by-design” is probably a reachable goal in the field of nanomedicine.
登录
查看更多内容
影响因子：
3.4
作者：
Burden, Natalie;Aschberger, Karin;Doak, Shareen H.
通讯作者：
Doak, Shareen H.
影响因子：
10.2
作者：
Fröhlich E
通讯作者：
Fröhlich E
影响因子：
5.4
作者：
Etheridge, Michael L.;Campbell, Stephen A.;Erdman, Arthur G.;Haynes, Christy L.;Wolf, Susan M.;McCullough, Jeffrey
通讯作者：
McCullough, Jeffrey
影响因子：
13.4
作者：
Allhoff, Fritz
通讯作者：
Allhoff, Fritz
影响因子：
4.3
作者：
Dusinska, Maria;Tulinska, Jana;Smolkova, Bozena
通讯作者：
Smolkova, Bozena